PhoreMost and NeoPhore Receive Innovate UK Funding to Support Development of a Novel Small-Molecule Cancer Immunotherapy Programme News - 27th April 2018
PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore, an Immuno-Oncology Company News - 15th November 2017
PhoreMost Ltd and University of Cambridge collaborate to identify innovative drug targets for neurodegenerative disease News - 12th October 2016
PhoreMost and The Wistar Institute Collaborate to Identify New Druggable Targets in Cancer, Immunotherapy and Aging News - 10th March 2016